O	0	10	Randomized
O	11	16	phase
O	17	19	II
O	20	25	study
O	26	28	of
B-intervention	29	40	anastrozole
I-intervention	41	45	plus
I-intervention	46	53	tegafur
I-intervention	53	54	-
I-intervention	54	60	uracil
O	61	63	as
O	64	75	neoadjuvant
O	76	83	therapy
O	84	87	for
O	88	90	ER
O	90	91	-
O	91	99	positive
O	100	106	breast
O	107	113	cancer
O	114	116	in
O	117	131	postmenopausal
O	132	140	Japanese
O	141	146	women
O	147	148	(
O	148	151	Neo
O	151	152	-
O	152	156	ACET
O	157	159	BC
O	159	160	)
O	160	161	.

O	162	166	This
O	167	172	phase
O	173	175	II
O	176	181	study
O	182	191	evaluated
O	192	195	the
O	196	204	efficacy
O	205	208	and
O	209	215	safety
O	216	218	of
O	219	230	anastrozole
O	231	241	concurrent
O	242	246	with
O	247	254	tegafur
O	254	255	/
O	255	261	uracil
O	262	263	(
O	263	266	UFT
O	266	267	)
O	268	270	as
O	271	282	neoadjuvant
O	283	290	therapy
O	291	294	for
O	295	297	ER
O	297	298	-
O	298	306	positive
O	307	321	postmenopausal
O	322	328	breast
O	329	335	cancer
O	335	336	.

O	337	351	Postmenopausal
B-ethinicity	352	360	Japanese
B-eligibility	361	366	women
I-eligibility	367	371	with
I-eligibility	372	374	ER
I-eligibility	374	375	-
I-eligibility	375	383	positive
I-eligibility	383	384	,
I-eligibility	385	389	HER2
I-eligibility	389	390	-
I-eligibility	390	398	negative
I-eligibility	398	399	,
I-eligibility	400	402	T2
I-eligibility	402	403	,
I-eligibility	403	405	N0
I-eligibility	405	406	-
I-eligibility	406	407	1
I-eligibility	407	408	,
I-eligibility	408	410	M0
I-eligibility	411	417	breast
I-eligibility	418	424	cancer
O	425	429	seen
O	430	432	at
O	433	441	tertiary
O	442	451	hospitals
O	452	456	were
O	457	465	eligible
O	466	469	for
O	470	474	this
O	475	479	open
O	479	480	-
O	480	485	label
O	485	486	,
O	487	497	randomized
O	497	498	,
O	499	510	multicenter
O	511	516	study
O	516	517	.

O	518	526	Patients
O	527	531	were
O	532	542	randomized
O	543	544	1
O	544	545	:
O	545	546	1
O	547	549	by
O	550	562	minimization
O	563	565	to
O	566	572	orally
O	573	580	receive
O	581	587	either
O	588	599	anastrozole
O	600	601	(
O	601	602	1
O	603	605	mg
O	606	610	once
O	611	616	daily
O	616	617	)
O	618	622	plus
O	623	626	UFT
O	627	628	(
O	628	635	tegafur
O	635	636	/
O	636	642	uracil
O	643	654	combination
O	655	657	in
O	658	659	1
O	659	660	:
O	660	661	4
O	662	667	molar
O	668	673	ratio
O	673	674	;
O	675	678	270
O	679	681	mg
O	681	682	/
O	682	684	m2
O	684	685	/
O	685	688	day
O	689	691	in
O	692	695	two
O	696	703	divided
O	704	709	doses
O	709	710	)
O	711	713	or
B-control	714	725	anastrozole
I-control	726	727	(
I-control	727	729	as
I-control	730	735	above
I-control	735	736	)
I-control	737	742	alone
O	743	746	for
O	747	749	24
O	750	755	weeks
O	755	756	.

O	757	762	Tumor
O	763	771	response
O	772	775	was
O	776	784	assessed
O	785	787	by
O	788	800	investigator
O	801	804	and
O	805	812	central
O	813	819	review
O	820	822	as
O	823	826	per
O	827	833	RECIST
O	834	836	v1
O	836	837	.
O	837	838	1
O	838	839	.

O	840	843	The
O	844	851	primary
O	852	860	endpoint
O	861	864	was
O	865	868	the
B-outcome-Measure	869	879	proportion
I-outcome-Measure	880	882	of
I-outcome-Measure	883	891	patients
I-outcome-Measure	892	896	with
I-outcome-Measure	897	901	best
I-outcome-Measure	902	909	overall
I-outcome-Measure	910	918	response
I-outcome-Measure	919	921	of
I-outcome-Measure	922	924	CR
I-outcome-Measure	925	927	or
I-outcome-Measure	928	930	PR
O	931	932	[
O	932	940	clinical
O	941	949	response
O	950	954	rate
O	955	956	(
O	956	958	RR
O	958	959	)
O	959	960	]
O	961	971	determined
O	972	974	by
O	975	982	central
O	983	993	radiologic
O	994	1000	review
O	1000	1001	.

O	1002	1005	The
O	1006	1011	study
O	1012	1015	was
O	1016	1027	prematurely
O	1028	1038	terminated
O	1039	1042	due
O	1043	1045	to
O	1046	1051	Grade
O	1052	1053	≥
O	1054	1055	3
O	1056	1061	liver
O	1062	1073	dysfunction
O	1074	1082	reported
O	1083	1085	in
O	1086	1087	3
O	1088	1096	patients
O	1097	1106	receiving
O	1107	1118	anastrozole
O	1118	1119	/
O	1119	1122	UFT
O	1122	1123	.

O	1124	1126	Of
B-total-participants	1127	1129	57
O	1130	1138	patients
O	1139	1149	randomized
O	1150	1156	before
O	1157	1168	termination
O	1169	1170	(
B-intervention-participants	1170	1172	29
O	1173	1184	anastrozole
O	1184	1185	/
O	1185	1188	UFT
O	1188	1189	,
B-control-participants	1190	1192	28
O	1193	1204	anastrozole
O	1204	1205	)
O	1205	1206	,
O	1207	1210	all
O	1211	1215	were
O	1216	1224	analyzed
O	1225	1228	for
O	1229	1235	safety
O	1236	1239	and
O	1240	1242	56
O	1243	1244	(
O	1244	1246	28
O	1247	1251	each
O	1252	1257	group
O	1257	1258	)
O	1259	1262	for
O	1263	1268	tumor
O	1269	1277	response
O	1277	1278	.

O	1279	1287	Compared
O	1288	1292	with
O	1293	1304	anastrozole
O	1305	1310	alone
O	1310	1311	,
O	1312	1323	anastrozole
O	1323	1324	/
O	1324	1327	UFT
O	1328	1331	did
O	1332	1335	not
O	1336	1343	achieve
O	1344	1357	significantly
O	1358	1364	higher
B-outcome	1365	1367	RR
O	1368	1369	[
B-iv-bin-abs	1369	1371	39
I-iv-bin-abs	1371	1372	.
I-iv-bin-abs	1372	1373	3
I-iv-bin-abs	1373	1374	%
O	1375	1376	(
O	1376	1378	90
O	1378	1379	%
O	1380	1382	CI
O	1383	1385	23
O	1385	1386	.
O	1386	1387	8
O	1387	1388	-
O	1388	1390	56
O	1390	1391	.
O	1391	1392	5
O	1392	1393	%
O	1393	1394	)
O	1395	1397	vs
B-cv-bin-percent	1398	1400	14
I-cv-bin-percent	1400	1401	.
I-cv-bin-percent	1401	1402	3
I-cv-bin-percent	1402	1403	%
O	1404	1405	(
O	1405	1407	90
O	1407	1408	%
O	1409	1411	CI
O	1412	1413	5
O	1413	1414	.
O	1414	1415	0
O	1415	1416	-
O	1416	1418	29
O	1418	1419	.
O	1419	1420	8
O	1420	1421	%
O	1421	1422	)
O	1422	1423	;
O	1424	1425	p
O	1426	1427	=
O	1428	1429	0
O	1429	1430	.
O	1430	1434	0683
O	1434	1435	,
O	1436	1442	Fisher
O	1442	1443	'
O	1443	1444	s
O	1445	1450	exact
O	1451	1455	test
O	1455	1456	]
O	1456	1457	,
O	1458	1461	but
O	1462	1470	produced
O	1471	1484	significantly
O	1485	1492	greater
B-outcome	1493	1498	tumor
I-outcome	1499	1508	shrinkage
O	1509	1510	(
O	1510	1514	mean
O	1515	1520	tumor
O	1521	1530	reduction
O	1531	1535	rate
B-iv-cont-mean	1536	1538	31
I-iv-cont-mean	1538	1539	.
I-iv-cont-mean	1539	1540	0
O	1541	1543	vs
O	1543	1544	.
B-cv-cont-mean	1545	1547	14
I-cv-cont-mean	1547	1548	.
I-cv-cont-mean	1548	1549	2
I-cv-cont-mean	1549	1550	%
O	1550	1551	;
O	1552	1553	p
O	1554	1555	=
O	1556	1557	0
O	1557	1558	.
O	1558	1562	0181
O	1562	1563	,
O	1564	1572	unpaired
O	1573	1574	t
O	1574	1575	-
O	1575	1579	test
O	1579	1580	)
O	1580	1581	.

B-outcome	1582	1587	Grade
I-outcome	1588	1589	≥
I-outcome	1590	1591	3
I-outcome	1592	1599	adverse
I-outcome	1600	1606	events
O	1607	1611	were
O	1612	1616	more
O	1617	1623	common
O	1624	1628	with
O	1629	1640	anastrozole
O	1640	1641	/
O	1641	1644	UFT
O	1645	1649	than
O	1650	1654	with
O	1655	1666	anastrozole
O	1667	1668	(
B-iv-bin-percent	1668	1670	17
I-iv-bin-percent	1670	1671	.
I-iv-bin-percent	1671	1672	2
O	1673	1675	vs
O	1675	1676	.
B-cv-bin-percent	1677	1678	0
I-cv-bin-percent	1678	1679	%
O	1679	1680	)
O	1680	1681	.

O	1682	1690	Although
O	1691	1694	the
O	1695	1700	study
O	1701	1704	was
O	1705	1715	terminated
O	1716	1721	owing
O	1722	1724	to
O	1725	1728	the
O	1729	1736	altered
O	1737	1742	liver
O	1743	1751	function
O	1751	1752	,
O	1753	1755	it
O	1756	1762	showed
O	1763	1767	that
O	1768	1773	there
O	1774	1777	was
O	1778	1779	a
O	1780	1785	trend
O	1786	1788	to
O	1789	1796	greater
O	1797	1806	shrinkage
O	1807	1809	of
O	1810	1815	tumor
O	1816	1818	in
O	1819	1822	the
O	1823	1834	combination
O	1835	1840	group
O	1841	1844	for
O	1845	1847	ER
O	1847	1848	-
O	1848	1856	positive
O	1856	1857	,
O	1858	1862	HER2
O	1862	1863	-
O	1863	1871	negative
O	1872	1886	postmenopausal
O	1887	1893	breast
O	1894	1900	cancer
O	1900	1901	.
